Clinical Trial Update: A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating abemaciclib (LY2835219) with and without food in metastatic breast cancer has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-08-13